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Glioblastoma multiforme (GBM), grade IV astrocytoma, is the most fatal malignant
primary brain tumor. GBM contains functional subsets of cells called glioblastoma stem-
like cells (GSCs), which are radioresistant and chemoresistant and eventually lead to
tumor recurrence. Recent studies showed that GSCs reside in particular tumor niches
that are necessary to support their behavior. To successfully eradicate GBM growth and
recurrence, new strategies selectively targeting GSCs and/or their microenvironmental
niche should be designed. In this regard, here we focus on elucidating the molecular
mechanisms that govern these GSC properties and on understanding the mechanism
of the microenvironmental signals within the tumor mass. Moreover, to overcome the
blood–brain barrier, which represents a critical limitation of GBM treatments, a new
drug delivery system should be developed. Nanoparticles can be easily modified by
different methods to facilitate delivery efficiency of chemotherapeutics, to enhance
the accumulation within the tumors, and to promote the capacity for targeting the
GSCs. Therefore, nanotechnology has become the most promising approach to
GSC-targeting therapy. Additionally, we discussed the future of nanotechnology-based
targeted therapy and point out the disadvantages that should be overcome.
Keywords: glioblastoma stem-like cells, tumor microenvironment, nanoparticle, epigenetic plasticity, nanocarrier
technologies
INTRODUCTION
Glioma is a type of tumor that arises from neoplastic glial cells. It makes up about 30% of
all cases of brain and central nervous system tumors and 80% of all malignant brain tumors
(Goodenberger and Jenkins, 2012). Glioblastoma multiforme (GBM), the most common and
fatal form of a primary brain tumor, accounts for approximately 60% of all glioma cases and is
categorized as grade IV glioma. GBM has a peak incidence in adults older than 40 years of age,
with 2.96 cases per 100,000 people per annum in the USA (Ostrom et al., 2015). Local invasiveness,
neoangiogenesis, and intratumor heterogeneity are among the most important hallmarks of the
aggressiveness of GBM (Jain et al., 2007; Aum et al., 2014; Paw et al., 2015). Conventional GBMs can
be subdivided into primary and secondary tumors on the basis of clinicopathologic stratification
(Kleihues and Ohgaki, 1999). Since 2008, the Cancer Genome Atlas (TCGA) Research Network has
generated a comprehensive catalog of genomic abnormalities driving tumorigenesis. With the help
Frontiers in Pharmacology | www.frontiersin.org 1 December 2016 | Volume 7 | Article 477
fphar-07-00477 December 7, 2016 Time: 12:19 # 2
Yi et al. Understanding and Targeting the GSCs
of this powerful tool, GBM is further categorized into
four main subtypes: classical, mesenchymal, proneural, and
neural type based on the mutational spectrum (Phillips
et al., 2006; Verhaak et al., 2010). Considering the striking
diversity among GBM subtypes and the clinical observation
that patients do not switch between subtypes during various
stages of this disease, different therapeutic strategies for
each group of GBM patients may yield more effective
outcomes.
The current standard treatment established by Stupp et al.
(2005) involves concomitant administration of temozolomide
with fractionated radiotherapy, with subsequent adjuvant
temozolomide. Despite the treatment advances and increased
understanding of the molecular and cellular mechanisms of
GBM, current therapy is rarely curative due to the infiltrative
nature of these tumors and their resistance to radiotherapy
and chemotherapy (Jhanwar-Uniyal et al., 2015). Even after
the maximal safe surgical resection, the residual tumor-
initiating cells (TICs) that infiltrate the surrounding brain
tissue could easily recapitulate the tumor and often become
more aggressive (Dick, 2008). Owing to the near-universal
tumor recurrence, patients with a diagnosis of GBM have
the median survival period of only 12–15 months, with only
10% of the patients surviving 5 years (Stupp et al., 2009).
These dismal outcomes reinforce the urgent need for novel
therapeutic strategies to beat this devastating disease. By means
of constant experiments and verification of the results, it is
believed that nanomaterials may be excellent carriers for tumor
therapy. According to the traits of nanomaterials, such as small
particle size, large specific surface area, easy modification,
quantum dynamical behavior, good permeability, and better
solubility than traditional drugs, nanomaterials have become
the promising drug carriers that are used for targeting the
central neural system. In addition to the research into drug
design, studies on characteristics of cancer cells and cancer
stem cells (CSCs) should also help to improve the curative
effect.
Compelling evidence suggests that CSCs play a major role
during initiation, progression, and recurrence of a tumor and are
primarily responsible for radiation and chemotherapy resistance
and poor survival of GBM patients (Bradshaw et al., 2016). It is,
therefore, not surprising that many therapeutic approaches have
been devised to specifically target CSCs, but still with limited
success (Seymour et al., 2015; Liebelt et al., 2016). The emerging
nanotechnology may serve as a powerful tool to overcome
the difficulties encountered with glioblastoma stem-like cell
(GSC)-targeting treatments. By modification of nanomaterials
researchers can effectively improve the capacity for transport
into brain parenchyma and for GSC targeting. For instance,
Kim et al. (2014) designed a cancer-targeting nanodelivery
platform system, which can carry a variety of drugs and
substances and can efficiently enhance the drug accumulation in
GSCs.
Thus, in this review, we summarize the key features of GSCs
and their microenvironmental niche. Then, we will discuss the
application of nanotechnology to the development of GSC-
targeting curative strategies and point out its future directions.
GSCs AND THEIR CHARACTERISTICS
According to the CSC hypothesis, tumors are hierarchically
organized and, at the apex of the hierarchy, are cells that
display stem cell properties. These properties include (a) self-
renewal, as well as the ability to differentiate into different cell
lineages forming the complexity of the tumor; (b) multiple drug
resistance and radiation resistance; (c) high tumorigenicity; (d)
similar signaling pathways as normal stem cells. In addition
to the above CSCs features, GSCs have the peculiarities of
cloning neurosphere-like clusters of cells. The presence of GSCs
was first demonstrated by the identification of a CD133+ cell
subpopulation that is capable of tumor initiation in vivo (Singh
et al., 2004). These tumor stem cells can form neurospheres
in vitro and share many characteristics with stem cells such as
the self-renewal ability and multipotent differentiation (Yuan
et al., 2004). Moreover, one report shows that two CSC
populations, which greatly differ in their growth properties
and tumor-initiating ability, can reside within distinct regions
of the same human GBM (Piccirillo et al., 2009). Therefore,
chemotherapy may not exactly target the active subtype of CSC
populations and thus have a poor curative effect. According
to the above theory, Sugimori et al. (2015) hypothesized
that in each cultured passage, heterogeneous clonal sublines
of a glioma sphere-forming model should display gradually
increased proliferative ability. But to their surprise, they found
that the self-renewal of heterogeneous GSC populations is
actually controlled by the power-law growth mechanism. The
power-law growth theory may be a promising development
in anticancer theories (Sugimori et al., 2015). Another latest
study suggests that differentiated GBM cells can be fully
reprogrammed into tumor stem-like cells by induction of
only four core transcription factors (TFs)—POU3F2, SOX2,
SALL2, and OLIG2, further supporting the GSC plasticity
and tumor hierarchy existing within GBM (Suvà et al.,
2014).
Stem Cell Markers in GBM
CD133, a cell surface marker of normal neural stem cells
(NSCs), is commonly used to distinguish GSCs (Singh et al.,
2004; Calabrese et al., 2007). One report revealed that as few
as 100 CD133+ cells are sufficient for the tumor initiation in
the brains of immunodeficient mice, which was not the case
for the CD133− population (Singh et al., 2004). In addition,
an increased proportion of CD133+ cells in GBM correlates
with worse prognosis and poorer survival (Zeppernick et al.,
2008; Metellus et al., 2011). The percentage of CD133+ cells is
significantly higher in recurrent GBMs after radiotherapy and
chemotherapy as compared with primary tumors (Tamura et al.,
2013). The CD133 signature effectively separates GBM from
lower-grade gliomas, and its enrichment has been attributed to
the aggressiveness of the tumor (Yan et al., 2011). Moreover,
CD133+ glioma cells, but not CD133− cells, interact closely
with vascular endothelial cells (ECs) in 3D Matrigel cultures
to form a perivascular niche that promotes the initiation of
brain tumors (Calabrese et al., 2007). Nonetheless, whether
CD133 can serve as a sole CSC marker for GBM has been
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questioned after a series of subsequent papers. Wang et al.
(2008a) demonstrated that CD133− subpopulations also have the
potential to initiate GBM tumor formation, and the xenograft
tumors initiated by CD133− cells are capable of producing
CD133+ progeny in vivo. Another study proved the expression
of nestin, glial fibrillary acidic protein (GFAP), and neuron-
specific enolase (NSE) in CD133− cells of GBM (Prestegarden
et al., 2010). After further isolation of cells using different
markers, the authors found that all these CD133− subpopulations
produce tumors without significant differences in survival or
tumor take rates. On the other hand, there was a trend toward
lower take rates for CD133− GBM subpopulations expressing
GFAP and NSE (Prestegarden et al., 2010). These observations
suggest that the stemness of GBM cells may not be identified
solely on the basis of CD133 expression. Apart from CD133,
several other cell surface markers such as SSEA-1, CD44, integrin
α6, L1CAM, and A2B5 have been used to enrich stem-like
populations in GBM (Son et al., 2009; Anido et al., 2010; Lathia
et al., 2010; Tchoghandjian et al., 2010; Cheng et al., 2011). The
effectiveness of these various cell surface stem cell markers is still
controversial.
Several key transcriptional factors involved in stem cell
maintenance are also proved to be highly expressed in
subpopulations of GSCs, such as c-Myc, SOX2, OCT4, NANOG,
SALL4, STAT3, Bmi1, and KLF4. Wang et al. (2008b) showed
that c-Myc is highly expressed in GSCs compared with non-stem
glioma cells. Knockdown of c-Myc in GSCs reduced proliferation
and increased apoptosis. But non-stem glioma cells did not
dependent on c-Myc signaling for survival. SOX2, OCT4, and
NANOG, which are critical in maintaining pluripotency in
ESCs, are known to be highly expressed in subpopulations of
GSCs, maintaining their self-renewal and cellular proliferation
(Wang et al., 2008b). Current research demonstrates positive
correlations between SOX2, OCT4, and NANOG expression
and pathological grade of gliomas. Furthermore, Zbinden et al.
(2010) showed that NANOG is preferentially expressed in GSCs
modulating the tumorigenicity, proliferation and gliomasphere
clonogenicity in GBM. By interacting with NANOG, SALL4 is
highly expressed in gliomas than in normal brain tissue and
correlates with a poor prognosis. Additionally, inhibition of
SALL4 decreases cellular proliferation in gliomas and promotes
apoptosis (Zbinden et al., 2010). But the use of SALL4 as
a marker for GSCs is still controversial. Sherry et al. (2009)
showed that STAT3 is a critical regulator of proliferation and
maintenance of multipotency in GSCs. Recent reports further
confirmed that loss of STAT3 suppressed tumorigenicity and
enhanced radiosensitivity of GSCs. Similarly, Abdouh et al.
(2009) showed that BMI1 is highly enriched in CD133-positive
cells in GBM tumors. Later, Baxter et al. (2014) found silencing
BMI1 eliminates tumor formation of pediatric glioma CD133+
cells. These findings highlighted the importance of BMI1 in
GSCs. Zhu et al. (2014) showed that the PGI-KLF4 pathway
regulates self-renewal of GSCs in human gliomas, suggesting
blockade of the PGI-KLF4 pathway may provide a therapeutic
strategy against GSCs. These studies reinforce the importance
of deep understanding of GSC markers. Proper validation of
these CSC markers will further refine the identification and
characterization of the CSC population in GBM and facilitate
successful treatment of malignancies.
Implicated Signaling Pathways
The qualities of multipotency and self-renewal are maintained
by the activation of a number of developmental signaling
pathways such as Notch, Sonic hedgehog (SHH), and Wnt
pathways, which are shared between NSCs and CSCs in GBM.
Increasing evidence suggests that aberrations of these signaling
pathways are implicated in the origin and maintenance of CSCs
in GBM.
The Notch pathway regulates the cell-lineage decisions during
embryogenesis and plays a critical role in the progression
of tumorigenesis such as proliferation, angiogenesis and cell
migration (Lasky and Wu, 2005; Leong and Karsan, 2006;
Dufraine et al., 2008). Notch-1 and its ligands are overexpressed
in many GBM cell lines and primary tumors and activation
of this pathway contributes to CSC survival and proliferation
(Purow et al., 2005; Kanamori et al., 2007). A recent study
confirmed that Notch blockade combined with a standard-
of-care treatment has an anti-CSC effect and provides an
improved survival benefit for GBM patients as well as
new insights for further clinical studies (Yahyanejad et al.,
2016).
Activation of the SHH pathway drives the development of
neural crest stem cells and the sympathetic nervous system (Wu
et al., 2010). Thus, it is not surprising that dysregulation of
the SHH pathway correlates with the central nervous system
tumorigenesis (Dahmane et al., 2001). The SHH pathway is
active in CSCs of GBM to maintain self-renewal and to induce
tumorigenesis by regulating the expression of stemness genes
(Clement et al., 2007). Inhibition of the SHH pathway by
cyclopamine specifically eliminates the CSC population in GBM
(Bar et al., 2007). Recently, Filbin et al. (2013) demonstrated
that inhibition of phosphatidylinositol 3-kinase (PI3K) and
SHH pathways synergistically reduces the growth of GBM
in vitro and in vivo, indicating a novel therapeutic approach to
GBM.
It is well-established that the Wnt/β-catenin signaling
pathway plays crucial roles in the regulation of embryogenesis,
homeostasis, regeneration, and stem cell pluripotency (Nelson
and Nusse, 2004). Numerous studies have elucidated the
regulatory connection between the Wnt/β-catenin signaling
pathway and GSCs. One report shows that glioma oncogene
PLAGL2 promotes gliomagenesis and maintains the stemness of
GSCs by activating the Wnt/β-catenin pathway (Zheng et al.,
2010). Another study revealed the direct interaction between TF
FoxM1 and β-catenin (Zhang et al., 2011). The FoxM1/β-catenin
interaction controls the self-renewal of GSCs and is required
for G2/M transition and proper mitotic progression. Further
research confirmed the upregulation of master stem cell regulator
SOX2 by FoxM1, which subsequently promotes the stemness
and radioresistance of GBM (Lee et al., 2015). In addition,
Jin et al. (2016) found that ectopic expression of inhibitor of
differentiation 1 (ID1) suppresses the CULLIN3 E3 ubiquitin
ligase and increases CYCLIN E protein stability in GBM.
Loss of CULLIN3 simultaneously activates WNT and SHH
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signaling and thus promotes the GSC properties (Jin et al.,
2016).
Contribution of Epigenetic Alterations to
GSCs
Aberrant epigenetic alterations are being increasingly recognized
as a major factor contributing to the pathogenesis of many
cancers, including GBM (Martinez et al., 2009; Kondo et al.,
2014). Epigenetic silencing of the O6-methylguanine-DNA
methyltransferase (MGMT) results in defective DNA repair
and is associated with longer survival among GBM patients,
indicating the significance of epigenetic mechanisms in
GBM development (Hegi et al., 2005). Because the stem
cell maintenance and differentiation require the precise
modeling of chromatin, epigenetic alterations may confer
a competitive advantage onto GSCs to adapt to the various
requirements of their malignant state and to the genetic
changes and environment. Stricker et al. (2013) demonstrated
that resetting of DNA methylation by induced pluripotent
stem cell reprogramming followed by lineage differentiation
suppresses the malignant properties of GBM. In addition,
comparative epigenomic analysis of chromatin maps revealed a
module of developmental TFs that is coordinately activated in
GSCs (Rheinbay et al., 2013). These TFs are essential for GSC
maintenance and are normally epigenetically silenced, pointing
to the existence of unique epigenetic regulatory programs in
GSCs.
Polycomb group (PcG) proteins are a family of epigenetic
regulators that regulate gene transcription by maintaining the
repressive or active chromatin state. Dysregulation of PcG is
thought to be closely related to the GSC maintenance and
in vivo tumorigenicity (Li et al., 2013; Signaroldi et al., 2016).
The polycomb repressor enhancer of zeste homolog 2 (EZH2)
is upregulated in GBM and plays a crucial role in GSC
maintenance (Suva et al., 2009). EZH2-dependent dysfunction
of the bone morphogenetic protein (BMP) pathway contributes
to the tumorigenicity of GSCs by both desensitizing GSCs
to normal differentiation cues and by converting cytostatic
signals to proproliferative signals (Lee et al., 2008). Another
polycomb repressor, Bmi1, is also proven to be required for
GBM development in an Ink4a/Arf-independent manner and
regulates the differentiation capacity of GSCs (Bruggeman et al.,
2007). Furthermore, very recent evidence shows that polycomb
dysregulation in gliomagenesis affects transcriptional networks
associated with invasiveness and dedifferentiation and indicates
that ZFP423 is a master PcG target mediating the differentiation
network (Signaroldi et al., 2016).
Some key developmental genes in GBM are also epigenetically
altered to facilitate the activation of stem cell-like properties.
Overexpression of the TF SOX2 has been reported in GBM
and is mainly caused by aberrant DNA promoter demethylation.
A knockdown of SOX2 in CSCs results in the loss of their self-
renewal properties; this finding is suggestive of the importance
of a pleiotropic role of SOX2 (Alonso et al., 2011). Another
study showed that expression of HIPPO pathway transcriptional
coactivator TAZ is silenced in lower-grade gliomas as well as
proneural GBMs when compared with mesenchymal tumors.
Functional analysis confirms that TAZ is a key modulator of
mesenchymal differentiation in GBM whose activity is regulated
epigenetically (Bhat et al., 2011). Nevertheless, at present, there
is limited knowledge about the mechanisms via which epigenetic
modifiers function in GSCs and the related therapeutic targeting.
THE MICROENVIRONMENT OF GSCs:
THE TUMOR VASCULAR NICHE
Cancer is an evolutionary and developmental process that is
not only driven by genetic variations but also strongly shaped
by numerous environmental factors. Accumulating evidence has
shown that cancers are closely associated with their surrounding
microenvironment consisting of neighboring cells, molecules,
and vascular and lymphatic networks (Weinberg, 2008; Junttila
and de Sauvage, 2013). As one of the most vascularized
solid tumors, GBM orchestrates vascular niches to maintain
self-renewal and survival of GSCs (Calabrese et al., 2007).
In turn, GSCs may also regulate the tumor vasculature and
subsequently promote the progression of tumor angiogenesis
(Jhaveri et al., 2016). Many efforts have been devoted to unveiling
the sophisticated interplay between GSCs and the tumor vascular
niche (Figure 1).
Tumor Vasculature in GBM
The human vasculature is a highly organized and dynamic
system providing essential paths for the body to transport
gasses, nutrients, waste products, or cells. In stark contrast to
normal blood vessels, tumor vasculature, especially in GBM,
forms a different network resulting in structural and functional
abnormalities such as irregular architecture, high permeability,
severe hypoxia, loss of hierarchy, and a compromised blood –
brain barrier (Jain et al., 2007). Normal blood vessels are
formed mainly by the mechanisms of vasculogenesis and
angiogenesis (Risau, 1997). Vasculogenesis is the process of
blood vessel formation occurring via de novo production
of endothelial progenitor cells (EPCs) during organogenesis
and fetal development, whereas angiogenesis represents the
process of new vessel development from preexisting vasculature
(Semenza, 2007). Construction of a primitive vascular network by
vasculogenesis and the following angiogenesis that is responsible
for expansion and remodeling of the existing vasculature
implement the formation of both normal and GBM vasculature.
In addition, two other types of neovascularization—vascular co-
option and vasculogenic mimicry—specifically characterize the
formation of GBM vasculature (Liebelt et al., 2016).
Promotion of Tumor Angiogenesis by
GSCs
The critical role of GSCs during glioma angiogenesis has been
widely studied. Vascular endothelial growth factor (VEGF), one
of the most important proangiogenic molecules, is significantly
upregulated in the medium of CD133+ GSCs as compared
to that of CD133− GSCs. This high level of VEGF promotes
human microvascular EC migration and tube formation
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FIGURE 1 | Schematic diagram of glioblastoma stem-like cell (GSC) microenvironment. GSCs are considered to be involved in many key events contribute
to the formation of GBM vascular niche, including the tumor angiogenesis, tumor vasculogenesis, vasculogenic mimicry, and pericyte differentiation.
(Bao et al., 2006). Further research suggested that GSCs
contribute to tumor angiogenesis by promoting both local
EC activity and systemic angiogenic processes involving bone
marrow-derived EPCs in a VEGF-dependent and stroma-
derived factor 1 (SDF-1)-dependent manner (Folkins et al.,
2009). Expression of VEGF and SDF-1 could be stimulated
in GSCs by hypoxia via activation of the PI3K/AKT signaling
pathway (Heddleston et al., 2009; Ping et al., 2011). In
addition, differential proteomic analysis indicates overexpression
of another proangiogenic factor, hepatoma-derived growth factor
(HDGF), in GSCs. Functional studies prove the role of HDGF
in promoting migration of human cerebral ECs in vitro and in
induction of neoangiogenesis in vivo (Thirant et al., 2012).
Involvement of GSCs in Tumor
Vasculogenesis via Transdifferentiation
into Endothelial Cells
Vasculogenesis is a de novo vascular formation through
the differentiation of EPCs during organogenesis and fetal
development. Emerging lines of evidence suggest that, besides
angiogenesis, tumor vascularization can also proceed via
endothelial transdifferentiation of GSCs (Folkins et al., 2009;
Ricci-Vitiani et al., 2010; Wang et al., 2010). Two independent
groups reported that a subpopulation of ECs in GBM harbors
the same genomic alterations as tumor cells, pointing to a
neoplastic origin of the tumor vascular endothelium (Ricci-
Vitiani et al., 2010; Wang et al., 2010). In particular, Wang et al.
(2010) suggest that CD133+ GSCs can give rise to intermediate
CD133+/CD144+ progenitor cells and subsequently differentiate
into ECs with the upregulation of CD105, CD31, CD34, and
VEGFR-2. Ricci-Vitiani et al. (2010) showed that CD133+ GSCs
grown under endothelial conditions generate microvascular
cultures of CD31+ and Tie2+ cells, and the vessels of a xenograft
tumor in immunocompromised mice formed by GSCs are
primarily composed of human CD31+ ECs. The presence of
tumor-derived ECs originating from GSCs was then verified by
Soda et al. (2011) using a genetically engineered mouse model of
GBM. Although, the significance of tumor vasculogenesis during
the development of GBM vasculature is still controversial as
compared with tumor angiogenesis (Rodriguez et al., 2012), it is
clear that GSCs may perform a critical function in both major
mechanisms formation of tumor vasculature.
Frontiers in Pharmacology | www.frontiersin.org 5 December 2016 | Volume 7 | Article 477
fphar-07-00477 December 7, 2016 Time: 12:19 # 6
Yi et al. Understanding and Targeting the GSCs
GSCs Contribute to Vasculogenic
Mimicry
In contrast to vasculogenesis, vasculogenic mimicry is defined as
the ability to form fluid-conducing vessel-like networks by highly
invasive tumor cells other than ECs (Chen and Chen, 2014).
One study identifies the tubular type blood vessels formed by
tumor cells in GBM tissues (El Hallani et al., 2010). Follow-up
experiments suggest that CD133+ GSCs can transdifferentiate
into smooth muscle-like cells that may constitute a part of the
tumor cell-lined vessel wall as the essential muscular component.
Yao et al. (2013) demonstrated the existence of non-EC-lined
vessels in GSC-derived murine xenograft tumors and human
primary GBM and further demonstrated that VEGF receptor 2
(VEGFR-2) is necessary for the formation of tubular structures
by GSCs. Moreover, Mao et al. (2013) confirmed the contribution
of CD144 to the vasculogenic mimicry of GSCs, especially under
hypoxic conditions.
GSCs Give Rise to Pericytes
Normal and tumor vessels share two distinct but interdependent
cellular components: ECs and vascular mural cells embedded
in the basement membrane of microvessels called pericytes
(Sweeney et al., 2016). Depletion of pericytes in tumor
vasculature suppresses tumor growth but enhances epithelial-
to-mesenchymal transition (EMT) and metastasis; these
observations are suggestive of the essential role of pericytes in
balancing cancer progression and metastasis (Cooke et al., 2012).
Emerging evidence shows that GSCs can give rise to pericytes
to support vessel function and facilitate tumor growth (Cheng
et al., 2013; Guichet et al., 2015). Cheng et al. (2013) suggest that
pericytes are commonly derived from neoplastic cells in GBM.
Selective elimination of pericytes by ganciclovir disrupts tumor
vessels and inhibits tumor growth. Functional studies revealed
that GSCs are recruited toward ECs via the SDF-1/CXCR4 axis,
and that the differentiation of GSCs into pericytes is induced
by TGF-β secretion (Cheng et al., 2013). A recent study showed
that Notch-1 stimulation triggers the expression of pericyte
cell markers in GSCs and generates highly vascularized and
poorly disseminating graft tumors containing GBM-derived
pericyte-like cells (Guichet et al., 2015). Moreover, TF HMGA2
was found to be expressed in both GSCs and pericytes of
GBM. Depletion of HMGA2 in GSCs abrogates their potential
for pericyte differentiation, indicating its role in self-renewal
properties of GSCs (Zhong et al., 2016).
GLIOBLASTOMA THERAPY
The traditional treatment program of malignant GBM is surgery,
radiotherapy, chemotherapy, and traditional Chinese medicine.
Because the growth characteristic of GBM is invasive growth,
there are no clear boundaries distinguishing the lesions from the
normal brain parenchyma. Surgical treatment cannot eliminate
the lesions. Residual cancer cells can lead to relapse. Thus,
surgery has limitations. In addition, there are limitations of
radiotherapy and chemotherapy respectively. Combining both
treatment strategies is more often used in GBM. Even so,
therapeutic benefits are still difficult to improve. Novel treatments
are urgently needed. Nanotechnology has several advantageous
characteristics that can be used in tumor therapy. In the
following subsection, we are going to expound the application of
nanotechnology to GBM management.
Nanoparticles are composed of artificial materials or natural
polymers, usually ranging in the grain diameter from 1 to
100 nm (Gabathuler, 2010). At present, most clinical nano-drug
diameters are approximately 10–1000 nm (Chen and Liu, 2012).
As compared to traditional chemotherapeutics, nanoparticles
have a much smaller grain diameter, larger specific surface
area, stronger adhesion, easier permeation through biological
barriers, better lipid solubility, and an accurate targeting ability.
Nanoparticles gradually assume a substantial role in tumor
therapy and targeted treatment of CSCs. Nanoparticles can be
modified by means of a variety of materials, which, for example,
can inhibit CSCs growth and renewal (Wang et al., 2011), increase
their biological barrier permeability, and improve targeting
of treatment. Modified nanoparticles effectively enhance the
transportation in the brain (Woodworth et al., 2014; Kim et al.,
2015).
TRANSPORT OF NANOPARTICLES TO
THE BRAIN
Drug delivery to the brain takes place via two pathways:
one way is intravenous injection that streams the drug to
intracerebral vessels and transfers them through the blood–brain
barrier (BBB) to brain parenchyma. Composed of tight junctions
between brain capillary ECs, the BBB maintains the stable
chemical microenvironment of the cerebral periphery and
prevents harmful substances from invading the brain. The
robust physical barrier ensures that 98% of small molecules and
whole macromolecules cannot pass through (Wei et al., 2014).
Meanwhile, the tight junction prevents the transmembrane
transport via paracellular route (Pardridge, 2006; Wong et al.,
2013).
The other way involves extravascular systems: cerebrospinal
fluid (CSF) and interstitial fluid (ISF).
The extravascular system of CSF is well-known. There
is ∼100–150 ml if CSF in human spinal canal circulating
every 4–5 h. CSF flows back into blood through arachnoid
granulation near the sagittal sinus that forms CSF and blood
circulation. Quantitative resistance ensures that is difficult for
macromolecular material to permeate through the arachnoid
granulation. We call the resistant entity the “blood–cerebrospinal
fluid barrier (BCSFB).” The solute exchange rate is much slower
in BCSFB than in BBB. As the result, the method of CSF drug
injection is rarely used for treatment of brain tumors (Pardridge,
2006). As the tumor grows, the BBB will be broken down
and increase its permeability. Tumor ECs help to develop new
vessels stretching into the tumor, yet the new vascular epithelial
cell junction is not tight enough. Because of the loose vessel
endothelium and a lack of lymphatics in tumor parenchyma,
it is easier for substances to flow into tumor parenchyma than
to flow out. This phenomenon is called solid tumor enhanced
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permeability and retention effect. Some investigators believe that
particle diameter greater than 100 nm makes it more difficult
for materials to pass through capillary walls; however, the grain
diameter less than 20 nm will make it easier for a material to
return to blood circulation. Thus, these researchers suggest that
particle diameters greater than 100 nm and less than 20 nm are
the best sizes for effective accumulation of a substance in tumor
tissue (Perrault et al., 2009).
Another extravascular system is the ISF. ISF is composed of
two parts: hydrostatic pressure and the colloid osmotic pressure.
The high interstitial fluid pressure (IFP) has been proved to
be a crucial barrier of drug delivery (Jain, 1987). Most solid
tumors have an increased IFP due to high vessel permeability,
poor perfusion, and high cell density around the blood vessels.
High IFP contributes to a low transcapillary transport in tumors,
therefore it is responsible for the decreased intake of drugs.
There are several types of regents to reduce tumor IFP in
animal models and patients, such as anti-angiogenic drugs
(VEGF inhibitors or PDGF inhibitors), TGF-beta inhibitors,
Dexamethasone, Bradykinin agonists, Nicotinamide, and pro-
inflammatory factor PGE1 (Heldin et al., 2004). In addition,
some chemotherapeutics, such as carboplatin and paclitaxel,
can enhance the effectiveness of anti-angiogenic drugs. Heist
et al. (2015) showed that combination of anti-VEGF and
chemotherapy improved the overall survival and the tumor
free period of patients with metastatic non-small lung cancer.
Zhou et al. (2008) found that VEGFR inhibitor, sunitinib,
enhanced tumor distribution of temozolomide due to vascular
normalization and stability and reduction in IFP. However,
Ribatti criticized that the vessel normalization followed by
normalization of permeability may become the obstacle to
chemotherapy (Ribatti, 2011). It might be true, but we think that
a better understanding of IFP mechanisms, and combination of
chemo-drugs, vascular normalization drugs, and the nanoparticle
delivery system to modulate IFP, may represent the new strategy
of glioma therapy.
A few soluble plasma molecules can be transported across
the BBB by the methods of bulk-phase/fluid-phase transcytosis
(FMT). This is because the cerebral epithelial cells possess
high-density clathrin-coated pits/vesicles that prevent negatively
charged ligands from FMT. Thus, only a few plasma proteins
such as albumin and immunoglobulin G transferrin can
randomly move across the BBB by FMT. According to
the characterization of clathrin-coated pits/vesicles, parts of
molecules can be transported by sinking into the clathrin-
coated cells membrane (Herve et al., 2008). This process
can be classified as receptor-mediated transcytosis (RMT) and
adsorption-mediated transcytosis (AMT) depending on the
transport mechanism. Nanoparticles can also be transported
across the BBB by means of the carrier-mediated transportation
(CMT), which usually transports big-molecule nutrients such as
glucose and acids (Figure 2). There are other methods such as the
paracellular aqueous pathway, transcellular lipophilic pathway,
cell-mediated transcytosis, and eﬄux pumps (Chen and Liu,
2012). Nonetheless, the efficiency of transport policies is not
satisfactory. How to break the transport limitations and design a
novel system for conveyance is a new challenge. In the following
subsection, we highlight the mechanisms of RMT, AMT, and
CMT that are used frequently for penetration of the BBB.
Receptor-Mediated Transportation
Receptor-mediated transcytosis relies on specific receptors on
the BBB that transport endogenous polymers depending on the
hydrolysis of ATP. It means that RMT has high specificity,
affinity, and energy dependence. Herve et al. (2008) indicated that
there are only a few peptides and proteins can be transported
through the BBB, e.g., insulin, insulin-like growth factors, iron-
transferrin, low density lipoprotein, and amyloid β proteins.
In recent years, more and more researchers report that large
molecules can pass through the RMT into the brain. Research
into transferrin receptor shows that The polyester poly (D,L-
lactide-co-glycolide) nanoparticles coated with transferrin can
improve the adhesion to the cell surface and endocytosis (Chang
et al., 2009). Otherwise, carbon nanospheres, large particles
ranging from 100 to 500 nm, were confirmed to cross the BBB
by clathrin-mediated endocytosis (Selvi et al., 2012).
Adsorptive-Mediated Transcytosis
The AMT mechanism is a non-specific process that does
not depend on the specific binding sites. Thus, the number
of receptor molecules has no influence on the capacity of
AMT. Transport is achieved by mutual attraction between a
positive charge on nanoparticles and a negative charge on
BBB EC membranes. Nonetheless, AMT has several undesirable
features: low affinity, a lack of specificity, and poor targeting
ability. Those characteristics limit practical applications of AMT.
AMT can transport only cationic proteins or cell-penetrating
peptides (Wei et al., 2014), e.g., antibody fragments, albumin,
histone, or protamine (Herve et al., 2008). Nevertheless, those
materials can combine with a variety of cargos, whereas
nanoparticles may slightly promote the drug delivery capacity
of AMT. Lu et al. (2005) discovered bovine serum albumin
conjugated with poly(ethyleneglycol)-poly(lactide) nanoparticles
(BSA-NPs), which cross the BBB by AMT with 7.76-fold higher
permeability after cationization (CBSA-NP)). The following
research indicates that the factor influencing the crossing of the
BBB by CBSA-NPs through AMT may be related to the surface
CBSA density of the particles. In addition, the mechanism of
CBSA-NP crossing the BBB through AMT is believed to involve
initial connection with the negative charge on the brain capillary
epithelial cells (Lu et al., 2007). These discoveries increased the
suitability of AMT for transport across the BBB.
Carrier-Mediated Transportation (CMT)
Blood–brain barrier ECs have been shown to have multiple
carrier proteins, which can transport glucose, amino acids,
nucleic acids, and other necessary nutrients across blood capillary
vessels to brain tissue. CMT has high substrate specificity where
those carriers bond only with particular endogenous substances.
Nanoparticles should simulate the designated substance that
can be transported across the BBB by CMT. The most
widely recognized carriers are glucose transporter proteins
(GLUTs). GLUT1 and GLUT3 are abundant in the mammalian
neurocyte membrane and brain capillary epithelium membrane
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FIGURE 2 | Schematic diagram of three blood–brain barrier (BBB) transport routes: receptor-mediated transportation (RMT), adsorptive-mediated
transportation (AMT), and carrier-mediated transportation (CMT). The glucose transporter protein (GLUT) is used to represent the structure of CMT. By
modifying the structure of nanoparticles can enhance the binding ability of drugs with the transporter.
(McEwen and Reagan, 2004). Especially, GLUT1 is the major
glucose transporter in the mammalian brain. Qin et al. (2010)
designed a system to load glucose on the liposome surface that
takes advantage of the transport by GLUT1. Jiang et al. (2014)
tested 2-deoxy-D-glucose modified poly(ethylene glycol)-co-
poly(trimethylene carbonate) nanoparticles (D-Glu-NP) loaded
with paclitaxel (PTX) and found that they have a greater ability
for transport across the BBB and less cytotoxicity than non-
glucosylated nanoparticles which are also loaded with PTX.
Because of the potential to increase penetration of the BBB via
GLUT-mediated transcytosis and the drug accumulative capacity
in GBM cancer cells via GLUT-mediated endocytosis, D-Glu-NP
became a promising targeting delivery system (Jiang et al., 2014).
CATEGORIES OF NANOPARTICLES
The ideal nanodrug should possess several merits: (a) high
efficiency of carrying drugs and generation of sufficient
concentration in the target cells, (b) low cytotoxicity and
immunogenicity (to be as harmless as possible for normal
somatic cells), (c) few side effects (to increase patients’ quality
of life), (d) stability in blood and prolonged blood circulation
time (Chen and Liu, 2012), and (f) low cost (should also be
expected). In the following subsection, we introduce four kinds
of nanoparticles, which are frequently used in conjunction with
varied chemotherapeutics, are reported to target GBM CSCs
(Table 1). By means of different modifications, nanoparticles’
ability to cross the BBB can be significantly enhanced. As a result
of nanoparticles’ enveloping the chemotherapeutics before the
drug is delivered to GBM, this approach may prevent normal cells
from being damaged and promote the targeting to GBM CSCs.
Liposomes
Liposomes are composed of a molecular phospholipid, which
forms the membrane-like double molecular phospholipids
structure. The diameter ranges from 20 nm to 100 µm. Traits of
great biocompatibility, non-toxicity, and biodegradability made
it a good carrier.
Kim’s research uncovered a tumor-targeting nanodelivery
platform called scL: it can carry diverse carriers and
systematically manage molecular drugs. As confirmed by
experiments on colonic cells (HT-29, HCT-116) and glioma cells
(U87, U251), liposomes may accumulate not only in non-cancer
stem cells: cancer stem-like cells also have efficient cumulative
effects. When liposomes carry wtp53 genes, these particles may
induce the death of cancer stem-like cells and growth inhibition.
This discovery potentially enhances the ability to prevent relapse
(Kim et al., 2014).
Polymeric Nanoparticles
These are kinds of solid colloid particles created from polymer
materials. The diameter ranges between 1 and 1000 nm. The most
popular application is linkage of polyethylene glycol (PEG) to
nanoparticle surfaces.
Lu et al. (2006) used cationic albumin-conjugated pegylated
nanoparticles (CBSA-NP) merged with plasmid pORF-hTRAIL
(pDNA) to perform non-viral gene therapy of cerebral glioma.
In vitro experiment, CBSA-NP-hTRAIL been observed that after
being transfected the C6 glioma cell they’re widely existed in the
cytoplasm. Lysosome in the cytoplasm gradually removed the
CBSA-NP and released the pDNA simultaneously. pDNA joined
the nuclei and induced apoptosis at 48 h after transfection. They,
then, intravenous injected CBSA-NP-hTRAIL into mice bearing
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C6 glioma. In vivo experiment verified CBSA-NP-hTRAIL can
efficiently accumulate in the glioma cells, instead of normal brain
cells. Lu’s study showed us that CBSA-NP-hTRAIL, which can
promote apoptosis and inhibit the tumor cell growth, may be a
potential non-invasive gene therapy of GBM (Lu et al., 2006).
Yang used cationic polyurethane with short branched chain
polymer of polyethylene imine (PU-PEI) as gene carriers, which
carried microRNA-145 (miR145): this is called PU-PEI-miR145
(Figure 3). This construct can efficiently inhibit expression of
multidrug resistance gene and anti-apoptotic gene in cerebral
glioma cancer stem-like cells, thereby increasing sensitivity
to radiotherapy and chemotherapy. Their research showed
that PU-PEI-miR145 can significantly reduce the tumorigenic
ability of malignant glioma CSCs in immunodeficient mice.
Immunodeficient mice were injected in situ with glioblastoma
and treated with the synergistic method of radiotherapy and
chemotherapy; this approach noticeably increased their survival
rate (Yang et al., 2012).
Gold Nanoparticles (GNPs)
The use of gold nanoparticles to kill tumor cells has been widely
reported, but applications aimed at killing tumor stem-like cells
are rare. Orza et al. (2013) reported a kind of a nanogold carrier
that, after loading with chemotherapy drugs, can selectively kill
glioma CSCs and promote uptake of the drug by the CSCs.
They used the gold nanoparticles treated with L-aspartate (GNP-
L-aspartate), which is a triangular-structure ligand. The mean
diameter was found to be ∼55 nm, and this aggregate can
FIGURE 3 | Schematic diagram of polymeric nanoparticles loading with microRNA-145 (miR-145). This miRNA-based therapeutic strategy can efficiently
inhibit expression of multidrug resistance gene and anti-apoptotic gene in cerebral GSCs (Tyagi et al., 2016).
TABLE 1 | The categories of nanotechnology application of GSCs.
Type Structure Characteristics Decoration Reference
Liposome Membrane-like double
molecular phospholipids
(a) Diameter ranged from 20 nm to 100 um
(b) Amphiphilic, biocompatible, non-toxicity,
and biodegradable
(a) scL Kim et al., 2014
Polymeric
Nanoparticle
A kind of solid colloid particles
created from polymer materials
(a) Diameter ranged between 1 and
1000 nm
(b) Water-soluble, non-toxic, biodegradable
(c) Easy-modified, drugs easy-combined
(a) PEG
(b) Cationic albumin-conjugated PEG
(c) PU-PEI-mi R145
Cho et al., 2008
Lu et al., 2006
Yang et al., 2012
Gold
Nanoparticle
Nanoscale metal particles (a) Properties of metal
(b) Easy-modified
(a) L-aspartate-TEM Orza et al., 2013
Nano-carbon
particle
Combined by graphene sheets (a) Great electrical properties
(b) Large specific area
(c) Ion adsorption
(d) Potential for gene delivery and detection
of biological molecules
(a) chitosan-CD133 monoclonal
antibodies
Wang et al., 2011
scL, a tumor-targeting nano-delivery platform discovered by Kim et al. (2014); PEG, polyethylene glycol; PU-PEI, cationic polyurethane with short branched chain polymer
of polyethylene imine; TEM, temozolomide.
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lengthen to become a chain ranging from 100 to 600 nm,
and can be combined with temozolomide (GNP-L-aspartate-
TEM). They found that there are some strong electrostatic
interactions between GNP-L-aspartate and TEM that make the
structure stable. Their research indicates that GNP-L-aspartate-
TEM can induce an apoptosis mechanism in almost 90% of
high-grade glioma-derived CSCs. This efficiency is better than
that of treatment with TEM alone (apoptosis in 42% of CSCs).
In addition, GNP-L-aspartate-TEM has higher bioactivity, lower
toxicity, and better capacity for targeting glioma-derived CSCs
(Orza et al., 2013).
Nanocarbon Particles
Assembled from graphene sheets, these nanoparticles can be in
several forms, e.g., carbon nanotubes or carbon nanospheres.
Carbon nanotubes have the potential for gene delivery and
detection of biological molecules (Cho et al., 2008). CD133
is recognized as the most validated malignant glioma CSC
marker (Singh et al., 2004). Attachment of CD133 monoclonal
antibodies onto carbon nanotubes that are modified by
chitosan results in the micelles with an average diameter
of ∼233 nm. Wang’s research confirmed that by means of
CD133 antibodies, nanotubes can target glioblastoma CD133+
cells (GBM-CD133+). They mixed the micelles and malignant
glioma cells and incubated them for some time, and then
proceeded to 808-nm laser radiotherapy. The results revealed that
GBM-CD133+ were eliminated clearly; however, GBM-CD133−
remained active. Those researchers subcutaneously injected the
GBM-CD133+ which underwent radiotherapy as mentioned
above into mice. Tumorigenicity and proliferation of GBM-
CD133+ was reduced (Wang et al., 2011).
FUTURE DIRECTIONS
For most chemical drugs, it is difficult to permeate the BBB. Even
though the chemotherapeutics cross the BBB, a large wasteful
dose is needed during the delivery process. This drawback may
decrease the curative efficiency. Furthermore, chemotherapeutics
have strong cytotoxicity: they not only damage cancer cells and
CSCs but also normal somatic cells. The use of nanoparticles
to carry the chemotherapeutics is a promising method that
improves their delivery. Nanoparticles have such advantages as
small grain diameter, large specific surface area, low toxicity, high
affinity, ease of modification, and the ability to carry multiple
cargoes. Encapsulation and chemical coupling technologies may
facilitate the transport across the BBB, promote targeting capacity
of varied drugs, and facilitate tumor diagnosis. There are
more and more modification methods for nanoparticles in the
literature. Yet, there are still a lot of unanswered questions:
(i) Selectivity of targeting to the brain tumor. This is a long-
standing question. To enhance the drug efficiency, we
expect a nanomedicine to successfully target the brain.
Nonetheless, most nanoparticles are non-specific, which
means they will also be delivered to other organs. This
situation makes accurate targeting to the brain cancer cells
or brain CSCs more difficult. Chen and Liu proposed using
multiple targeting ligands, which are selected according
to the pathological conditions of the disease and may
thus successfully solve these problems (Chen and Liu,
2012). Yao et al. (2015) made some progress in tumor
diagnosis techniques. Nanotheranostics is an emerging
subject that often involves the diagnosis by means of
magnetic nanoparticles, which can be imaged via magnetic
resonance and hold great promise for beaconing the tumor
position. Current research shows that magnetic nanoparticles
are not only beacons but also promising drug delivery agents.
They can target a brain tumor, control the release of drugs,
and induce hyperthermia (Yao et al., 2015).
(ii) Individualized therapy. Because each individual has different
receptor sensitivity, despite being given the same dose of
drugs, the pharmacodynamics will differ among people. This
notion highlights the importance of personalized treatment.
(iii) How to monitor the accumulation of nanodrugs in a brain
tumor? There are many studies addressing this question and
showing that the use of the iconography technology can
detect the nanodrug at the nanoscale (Pohlmann et al., 2015).
(iv) Toxicity. Past and present studies have usually been focused
on the reduction in cytotoxicity of the chemotherapeutics
and often overlooked the issues with safety of the
nanoparticles or nanodrugs. When nanoparticles are used
in a treatment strategy, they should be rigorously analyzed
as a clinical medication. Yet, there is no reference standard
of toxicity. It is important to establish a set of standardized
testing strategies for the safety assessment of nanodrugs
(Elsaesser and Howard, 2012; Nystrom and Fadeel, 2012).
Besides, the biological and toxicological behavior mostly
depends on how the nanoparticles come into contact with
a nanoscale biological structure. Elucidation of the laws
governing the behavior of a bio-nano-interface in vivo may
expand the practical applications of nanomedicine (Nystrom
and Fadeel, 2012). Therefore, we look forward to the new
knowledge that will be generated by researchers in the field
of nanomaterials.
AUTHOR CONTRIBUTIONS
YY and I-YH summarized the literature and wrote the
manuscript. XH drew the figures and revised the manuscript. JL
and WZ supervised all the work and finalized the manuscript.
FUNDING
This work was supported by National Science Foundation of
China (No. 81572766) and SYSU Young Teachers Training
Program (No. 16YKZD14).
ACKNOWLEDGMENT
We thank Dr. Jingxin Mo and Miss. Bin Lu for valuable
suggestions.
Frontiers in Pharmacology | www.frontiersin.org 10 December 2016 | Volume 7 | Article 477
fphar-07-00477 December 7, 2016 Time: 12:19 # 11
Yi et al. Understanding and Targeting the GSCs
REFERENCES
Abdouh, M., Facchino, S., Chatoo, W., Balasingam, V., Ferreira, J., and Bernier, G.
(2009). BMI1 sustains human glioblastoma multiforme stem cell renewal.
J. Neurosci. 29, 8884–8896. doi: 10.1523/JNEUROSCI.0968-09.2009
Alonso, M. M., Diez-Valle, R., Manterola, L., Rubio, A., Liu, D., Cortes-
Santiago, N., et al. (2011). Genetic and epigenetic modifications of Sox2
contribute to the invasive phenotype of malignant gliomas. PLoS ONE 6:e26740.
doi: 10.1371/journal.pone.0026740
Anido, J., Saez-Borderias, A., Gonzalez-Junca, A., Rodon, L., Folch, G.,
Carmona, M. A., et al. (2010). TGF-beta receptor inhibitors target
the CD44(high)/Id1(high) glioma-initiating cell population in human
glioblastoma. Cancer Cell 18, 655–668. doi: 10.1016/j.ccr.2010.10.023
Aum, D. J., Kim, D. H., Beaumont, T. L., Leuthardt, E. C., Dunn, G. P., and
Kim, A. H. (2014). Molecular and cellular heterogeneity: the hallmark of
glioblastoma. Neurosurg. Focus 37, E11. doi: 10.3171/2014.9.FOCUS14521
Bao, S. D., Wu, Q. L., Sathornsumetee, S., Hao, Y. L., Li, Z. Z., Hjelmeland, A. B.,
et al. (2006). Stem cell-like glioma cells promote tumor angiogenesis through
vascular endothelial growth factor. Cancer Res. 66, 7843–7848. doi: 10.1158/
0008-5472.CAN-06-1010
Bar, E. E., Chaudhry, A., Lin, A., Fan, X., Schreck, K., Matsui, W., et al. (2007).
Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer
cells in glioblastoma. Stem Cells 25, 2524–2533. doi: 10.1634/stemcells.2007-
0166
Baxter, P. A., Lin, Q., Mao, H., Kogiso, M., Zhao, X., Liu, Z., et al. (2014). Silencing
BMI1 eliminates tumor formation of pediatric glioma CD133+ cells not by
affecting known targets but by down-regulating a novel set of core genes. Acta
Neuropatho.l Commun. 2:160. doi: 10.1186/s40478-014-0160-4
Bhat, K. P., Salazar, K. L., Balasubramaniyan, V., Wani, K., Heathcock, L.,
Hollingsworth, F., et al. (2011). The transcriptional coactivator TAZ regulates
mesenchymal differentiation in malignant glioma. Genes Dev. 25, 2594–2609.
doi: 10.1101/gad.176800.111
Bradshaw, A., Wickremsekera, A., Tan, S. T., Peng, L., Davis, P. F., and Itinteang, T.
(2016). Cancer stem cell hierarchy in glioblastoma multiforme. Front. Surg.
3:21. doi: 10.3389/fsurg.2016.00021
Bruggeman, S. W., Hulsman, D., Tanger, E., Buckle, T., Blom, M., Zevenhoven, J.,
et al. (2007). Bmi1 controls tumor development in an Ink4a/Arf-independent
manner in a mouse model for glioma. Cancer Cell 12, 328–341. doi: 10.1016/j.
ccr.2007.08.032
Calabrese, C., Poppleton, H., Kocak, M., Hogg, T. L., Fuller, C., Hamner, B., et al.
(2007). A perivascular niche for brain tumor stem cells. Cancer Cell 11, 69–82.
doi: 10.1016/j.ccr.2006.11.020
Chang, J., Jallouli, Y., Kroubi, M., Yuan, X. B., Feng, W., Kang, C. S., et al. (2009).
Characterization of endocytosis of transferrin-coated PLGA nanoparticles by
the blood-brain barrier. Int. J. Pharm. 379, 285–292. doi: 10.1016/j.ijpharm.
2009.04.035
Chen, Y., and Liu, L. (2012). Modern methods for delivery of drugs across the
blood-brain barrier. Adv. Drug Deliv. Rev. 64, 640–665. doi: 10.1016/j.addr.
2011.11.010
Chen, Y. S., and Chen, Z. P. (2014). Vasculogenic mimicry: a novel target for glioma
therapy. Chin. J. Cancer 33, 74–79. doi: 10.5732/cjc.012.10292
Cheng, L., Huang, Z., Zhou, W., Wu, Q., Donnola, S., Liu, J. K., et al. (2013).
Glioblastoma stem cells generate vascular pericytes to support vessel function
and tumor growth. Cell 153, 139–152. doi: 10.1016/j.cell.2013.02.021
Cheng, L., Wu, Q. L., Huang, Z., Guryanova, O. A., Huang, Q. A., Shou, W. N., et al.
(2011). L1CAM regulates DNA damage checkpoint response of glioblastoma
stem cells through NBS1. EMBO J. 30, 800–813. doi: 10.1038/emboj.2011.10
Cho, K., Wang, X., Nie, S., Chen, Z. G., and Shin, D. M. (2008). Therapeutic
nanoparticles for drug delivery in cancer. Clin. Cancer Res. 14, 1310–1316.
doi: 10.1158/1078-0432.CCR-07-1441
Clement, V., Sanchez, P., de Tribolet, N., Radovanovic, I., and Ruiz i Altaba, A.
(2007). HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer
stem cell self-renewal, and tumorigenicity. Curr. Biol. 17, 165–172. doi: 10.1016/
j.cub.2007.01.024
Cooke, V. G., LeBleu, V. S., Keskin, D., Khan, Z., O’Conne, J. T., Teng, Y.,
et al. (2012). Pericyte depletion results in hypoxia-associated epithelial-to-
mesenchymal transition and metastasis mediated by met signaling pathway.
Cancer Cell 21, 66–81. doi: 10.1016/j.ccr.2011.11.024
Dahmane, N., Sanchez, P., Gitton, Y., Palma, V., Sun, T., Beyna, M., et al.
(2001). The sonic hedgehog-gli pathway regulates dorsal brain growth and
tumorigenesis. Development 128, 5201–5212.
Dick, J. E. (2008). Stem cell concepts renew cancer research. Blood 112, 4793–4807.
doi: 10.1182/blood-2008-08-077941
Dufraine, J., Funahashi, Y., and Kitajewski, J. (2008). Notch signaling regulates
tumor angiogenesis by diverse mechanisms. Oncogene 27, 5132–5137. doi: 10.
1038/onc.2008.227
El Hallani, S., Boisselier, B., Peglion, F., Rousseau, A., Colin, C., Idbaih, A., et al.
(2010). A new alternative mechanism in glioblastoma vascularization: tubular
vasculogenic mimicry. Brain 133, 973–982. doi: 10.1093/brain/awq044
Elsaesser, A., and Howard, C. V. (2012). Toxicology of nanoparticles. Adv. Drug
Deliv. Rev. 64, 129–137. doi: 10.1016/j.addr.2011.09.001
Filbin, M. G., Dabral, S. K., Pazyra-Murphy, M. F., Ramkissoon, S., Kung, A. L.,
Pak, E., et al. (2013). Coordinate activation of Shh and PI3K signaling in PTEN-
deficient glioblastoma: new therapeutic opportunities.Nat.Med. 19, 1518–1523.
doi: 10.1038/nm.3328
Folkins, C., Shaked, Y., Man, S., Tang, T., Lee, C. R., Zhu, Z., et al. (2009).
Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis
via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res.
69, 8216–8216. doi: 10.1158/0008-5472.CAN-09-0167
Gabathuler, R. (2010). Approaches to transport therapeutic drugs across the blood-
brain barrier to treat brain diseases. Neurobiol. Dis. 37, 48–57. doi: 10.1016/j.
nbd.2009.07.028
Goodenberger, M. L., and Jenkins, R. B. (2012). Genetics of adult glioma. Cancer
Genet. 205, 613–621. doi: 10.1016/j.cancergen.2012.10.009
Guichet, P. O., Guelfi, S., Teigell, M., Hoppe, L., Bakalara, N., Bauchet, L., et al.
(2015). Notch1 stimulation induces a vascularization switch with pericyte-like
cell differentiation of glioblastoma stem cells. Stem Cells 33, 21–34. doi: 10.1002/
stem.1767
Heddleston, J. M., Li, Z., McLendon, R. E., Hjelmeland, A. B., and Rich, J. N.
(2009). The hypoxic microenvironment maintains glioblastoma stem cells and
promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8,
3274–3284. doi: 10.4161/cc.8.20.9701
Hegi, M. E., Diserens, A. C., Gorlia, T., Hamou, M. F., de Tribolet, N., Weller, M.,
et al. (2005). MGMT gene silencing and benefit from temozolomide in
glioblastoma. N. Engl. J. Med. 352, 997–1003. doi: 10.1056/NEJMoa043331
Heist, R. S., Duda, D. G., Sahani, D. V., Ancukiewicz, M., Fidias, P., Sequist, L. V.,
et al. (2015). Improved tumor vascularization after anti-VEGF therapy with
carboplatin and nab-paclitaxel associates with survival in lung cancer. Proc.
Natl. Acad. Sci. U.S.A. 112, 1547–1552. doi: 10.1073/pnas.1424024112
Heldin, C.-H., Rubin, K., Pietras, K., and Östman, A. (2004). High interstitial
fluid pressure — an obstacle in cancer therapy. Nat. Rev. Cancer 4, 806–813.
doi: 10.1038/nrc1456
Herve, F., Ghinea, N., and Scherrmann, J. M. (2008). CNS delivery via adsorptive
transcytosis. AAPS J. 10, 455–472. doi: 10.1208/s12248-008-9055-2
Jain, R. K. (1987). Transport of molecules across tumor vasculature. Cancer
Metastasis Rev. 6, 559–593. doi: 10.1007/BF00047468
Jain, R. K., di Tomaso, E., Duda, D. G., Loeﬄer, J. S., Sorensen, A. G., and Batchelor,
T. T. (2007). Angiogenesis in brain tumours. Nat. Rev. Neurosci. 8, 610–622.
doi: 10.1038/nrn2175
Jhanwar-Uniyal, M., Labagnara, M., Friedman, M., Kwasnicki, A., and Murali, R.
(2015). Glioblastoma: molecular pathways, stem cells and therapeutic targets.
Cancers 7, 538–555. doi: 10.3390/cancers7020538
Jhaveri, N., Chen, T. C., and Hofman, F. M. (2016). Tumor vasculature and glioma
stem cells: contributions to glioma progression. Cancer Lett. 380, 545–551.
doi: 10.1016/j.canlet.2014.12.028**
Jiang, X., Xin, H., Ren, Q., Gu, J., Zhu, L., Du, F., et al. (2014). Nanoparticles of
2-deoxy-D-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene
carbonate) for dual-targeted drug delivery in glioma treatment. Biomaterials 35,
518–529. doi: 10.1016/j.biomaterials.2013.09.094
Jin, X., Jeon, H. M., Kim, E. J., Yin, J., Jeon, H. Y., Sohn, Y. W., et al. (2016).
The ID1-CULLIN3 axis regulates intracellular SHH and WNT signaling in
glioblastoma stem cells. Cell Rep. 16, 1629–1641. doi: 10.1016/j.celrep.2016.06.
092
Junttila, M. R., and de Sauvage, F. J. (2013). Influence of tumour micro-
environment heterogeneity on therapeutic response. Nature 501, 346–354. doi:
10.1038/nature12626
Frontiers in Pharmacology | www.frontiersin.org 11 December 2016 | Volume 7 | Article 477
fphar-07-00477 December 7, 2016 Time: 12:19 # 12
Yi et al. Understanding and Targeting the GSCs
Kanamori, M., Kawaguchi, T., Nigro, J. M., Feuerstein, B. G., Berger, M. S.,
Miele, L., et al. (2007). Contribution of Notch signaling activation to human
glioblastoma multiforme. J. Neurosurg. 106, 417–427. doi: 10.3171/jns.2007.106.
3.417
Kim, S. S., Harford, J. B., Pirollo, K. F., and Chang, E. H. (2015). Effective treatment
of glioblastoma requires crossing the blood-brain barrier and targeting tumors
including cancer stem cells: the promise of nanomedicine. Biochem. Biophys.
Res. Commun. 468, 485–489. doi: 10.1016/j.bbrc.2015.06.137
Kim, S. S., Rait, A., Rubab, F., Rao, A. K., Kiritsy, M. C., Pirollo, K. F., et al. (2014).
The clinical potential of targeted nanomedicine: delivering to cancer stem-like
cells. Mol. Ther. 22, 278–291. doi: 10.1038/mt.2013.231
Kleihues, P., and Ohgaki, H. (1999). Primary and secondary glioblastomas: from
concept to clinical diagnosis. Neuro Oncol. 1, 44–51. doi: 10.1215/15228517-1-
1-44
Kondo, Y., Katsushima, K., Ohka, F., Natsume, A., and Shinjo, K. (2014). Epigenetic
dysregulation in glioma. Cancer Sci. 105, 363–369. doi: 10.1111/cas.12379
Lasky, J. L., and Wu, H. (2005). Notch signaling, brain development, and human
disease. Pediatr. Res. 57(5 Pt 2), 104R–109R. doi: 10.1203/01.PDR.0000159632.
70510.3D
Lathia, J. D., Gallagher, J., Heddleston, J. M., Wang, J. L., Eyler, C. E., MacSwords, J.,
et al. (2010). Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 6,
421–432. doi: 10.1016/j.stem.2010.02.018
Lee, J., Son, M. J., Woolard, K., Donin, N. M., Li, A., Cheng, C. H., et al. (2008).
Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway
inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 13, 69–80.
doi: 10.1016/j.ccr.2007.12.005
Lee, Y., Kim, K. H., Kim, D. G., Cho, H. J., Kim, Y., Rheey, J., et al. (2015).
FoxM1 promotes stemness and radio-resistance of glioblastoma by regulating
the master stem cell regulator Sox2. PLoS ONE 10:e0137703. doi: 10.1371/
journal.pone.0137703
Leong, K. G., and Karsan, A. (2006). Recent insights into the role of Notch signaling
in tumorigenesis. Blood 107, 2223–2233. doi: 10.1182/blood-2005-08-3329
Li, G., Warden, C., Zou, Z., Neman, J., Krueger, J. S., Jain, A., et al. (2013). Altered
expression of polycomb group genes in glioblastoma multiforme. PLoS ONE
8:e80970. doi: 10.1371/journal.pone.0080970
Liebelt, B. D., Shingu, T., Zhou, X., Ren, J., Shin, S. A., and Hu, J. (2016). Glioma
Stem Cells: Signaling, Microenvironment, and Therapy. Stem Cells Int. 2016:
7849890. doi: 10.1155/2016/7849890
Lu, W., Sun, Q., Wan, J., She, Z., and Jiang, X. G. (2006). Cationic albumin-
conjugated pegylated nanoparticles allow gene delivery into brain tumors via
intravenous administration. Cancer Res. 66, 11878–11887. doi: 10.1158/0008-
5472.CAN-06-2354
Lu, W., Wan, J., She, Z., and Jiang, X. (2007). Brain delivery property
and accelerated blood clearance of cationic albumin conjugated pegylated
nanoparticle. J. Control. Release 118, 38–53. doi: 10.1016/j.jconrel.2006.11.015
Lu, W., Zhang, Y., Tan, Y. Z., Hu, K. L., Jiang, X. G., and Fu, S. K. (2005). Cationic
albumin-conjugated pegylated nanoparticles as novel drug carrier for brain
delivery. J. Control. Release 107, 428–448. doi: 10.1016/j.jconrel.2005.03.027
Mao, X. G., Xue, X. Y., Wang, L., Zhang, X., Yan, M., Tu, Y. Y., et al. (2013).
CDH5 is specifically activated in glioblastoma stemlike cells and contributes
to vasculogenic mimicry induced by hypoxia. Neuro Oncol. 15, 865–879. doi:
10.1093/neuonc/not029
Martinez, R., Martin-Subero, J. I., Rohde, V., Kirsch, M., Alaminos, M., Fernandez,
A. F., et al. (2009). A microarray-based DNA methylation study of glioblastoma
multiforme. Epigenetics 4, 255–264. doi: 10.4161/epi.9130
McEwen, B. S., and Reagan, L. P. (2004). Glucose transporter expression in the
central nervous system: relationship to synaptic function. Eur. J. Pharmacol.
490, 13–24. doi: 10.1016/j.ejphar.2004.02.041
Metellus, P., Nanni-Metellus, I., Delfino, C., Colin, C., Tchogandjian, A.,
Coulibaly, B., et al. (2011). Prognostic impact of CD133 mRNA expression
in 48 glioblastoma patients treated with concomitant radiochemotherapy:
a prospective patient cohort at a single institution. Ann. Surg. Oncol. 18,
2937–2945. doi: 10.1245/s10434-011-1703-6
Nelson, W. J., and Nusse, R. (2004). Convergence of Wnt, beta-catenin, and
cadherin pathways. Science 303, 1483–1487. doi: 10.1126/science.1094291
Nystrom, A. M., and Fadeel, B. (2012). Safety assessment of nanomaterials:
implications for nanomedicine. J. Control. Release 161, 403–408. doi: 10.1016/j.
jconrel.2012.01.027
Orza, A., Soritau, O., Tomuleasa, C., Olenic, L., Florea, A., Pana, O., et al.
(2013). Reversing chemoresistance of malignant glioma stem cells using
gold nanoparticles. Int. J. Nanomedicine 8, 689–702. doi: 10.2147/IJN.
S37481
Ostrom, Q. T., Gittleman, H., Fulop, J., Liu, M., Blanda, R., Kromer, C., et al.
(2015). CBTRUS statistical report: primary brain and central nervous system
tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 17(Suppl. 4),
iv1–iv62. doi: 10.1093/neuonc/nou327
Pardridge, W. M. (2006). Molecular Trojan horses for blood-brain barrier drug
delivery. Discov. Med. 6, 139–143.
Paw, I., Carpenter, R. C., Watabe, K., Debinski, W., and Lo, H. W. (2015).
Mechanisms regulating glioma invasion. Cancer Lett. 362, 1–7. doi: 10.1016/
j.canlet.2015.03.015
Perrault, S. D., Walkey, C., Jennings, T., Fischer, H. C., and Chan, W. C. (2009).
Mediating tumor targeting efficiency of nanoparticles through design. Nano
Lett. 9, 1909–1915. doi: 10.1021/nl900031y
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D.,
et al. (2006). Molecular subclasses of high-grade glioma predict prognosis,
delineate a pattern of disease progression, and resemble stages in neurogenesis.
Cancer Cell 9, 157–173. doi: 10.1016/j.ccr.2006.02.019
Piccirillo, S. G. M., Combi, R., Cajola, L., Patrizi, A., Redaelli, S., Bentivegna, A.,
et al. (2009). Distinct pools of cancer stem-like cells coexist within human
glioblastomas and display different tumorigenicity and independent genomic
evolution. Oncogene 28, 1807–1811. doi: 10.1038/onc.2009.27
Ping, Y. F., Yao, X. H., Jiang, J. Y., Zhao, L. T., Yu, S. C., Jiang, T., et al. (2011).
The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-
mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling.
J. Pathol. 224, 344–354. doi: 10.1002/path.2908
Pohlmann, E. S., Patel, K., Guo, S., Dukes, M. J., Sheng, Z., and Kelly,
D. F. (2015). Real-time visualization of nanoparticles interacting with
glioblastoma stem cells. Nano Lett. 15, 2329–2335. doi: 10.1021/nl50
4481k
Prestegarden, L., Svendsen, A., Wang, J., Sleire, L., Skaftnesmo, K. O., Bjerkvig, R.,
et al. (2010). Glioma cell populations grouped by different cell type markers
drive brain tumor growth. Cancer Res. 70, 4274–4279. doi: 10.1158/0008-5472.
CAN-09-3904
Purow, B. W., Haque, R. M., Noel, M. W., Su, Q., Burdick, M. J., Lee, J., et al.
(2005). Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is
critical for glioma cell survival and proliferation. Cancer Res. 65, 2353–2363.
doi: 10.1158/0008-5472.CAN-04-1890
Qin, Y., Fan, W., Chen, H., Yao, N., Tang, W., Tang, J., et al. (2010). In vitro and
in vivo investigation of glucose-mediated brain-targeting liposomes. J. Drug
Target. 18, 536–549. doi: 10.3109/10611861003587235
Rheinbay, E., Suva, M. L., Gillespie, S. M., Wakimoto, H., Patel, A. P., Shahid, M.,
et al. (2013). An aberrant transcription factor network essential for Wnt
signaling and stem cell maintenance in glioblastoma. Cell Rep. 3, 1567–1579.
doi: 10.1016/j.celrep.2013.04.021
Ribatti, D. (2011). Vascular normalization: a real benefit? Cancer Chemother.
Pharmacol. 68, 275–278. doi: 10.1007/s00280-011-1683-z
Ricci-Vitiani, L., Pallini, R., Biffoni, M., Todaro, M., Invernici, G., Cenci, T.,
et al. (2010). Tumour vascularization via endothelial differentiation of
glioblastoma stem-like cells. Nature 468, 824–828. doi: 10.1038/nature
09557
Risau, W. (1997). Mechanisms of angiogenesis. Nature 386, 671–674. doi: 10.1038/
386671a0
Rodriguez, F. J., Orr, B. A., Ligon, K. L., and Eberhart, C. G. (2012). Neoplastic cells
are a rare component in human glioblastoma microvasculature. Oncotarget 3,
98–106.
Selvi, R. B., Chatterjee, S., Jagadeesan, D., Chaturbedy, P., Suma, B. S.,
Eswaramoorthy, M., et al. (2012). ATP driven clathrin dependent entry of
carbon nanospheres prefer cells with glucose receptors. J. Nanobiotechnol. 10:
35. doi: 10.1186/1477-3155-10-35
Semenza, G. L. (2007). Vasculogenesis, angiogenesis, and arteriogenesis:
mechanisms of blood vessel formation and remodeling. J. Cell. Biochem.
102, 840–847. doi: 10.1002/jcb.21523
Seymour, T., Nowak, A., and Kakulas, F. (2015). Targeting aggressive cancer
stem cells in glioblastoma. Front. Oncol. 5:159. doi: 10.3389/fonc.2015.
00159
Frontiers in Pharmacology | www.frontiersin.org 12 December 2016 | Volume 7 | Article 477
fphar-07-00477 December 7, 2016 Time: 12:19 # 13
Yi et al. Understanding and Targeting the GSCs
Sherry, M. M., Reeves, A., Wu, J. K., and Cochran, B. H. (2009). STAT3 is required
for proliferation and maintenance of multipotency in glioblastoma stem cells.
Stem Cells 27, 2383–2392. doi: 10.1002/stem.185
Signaroldi, E., Laise, P., Cristofanon, S., Brancaccio, A., Reisoli, E., Atashpaz, S.,
et al. (2016). Polycomb dysregulation in gliomagenesis targets a Zfp423-
dependent differentiation network. Nat. Commun. 7:10753. doi: 10.1038/
ncomms10753
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., et al. (2004).
Identification of human brain tumour initiating cells. Nature 432, 396–401.
doi: 10.1038/nature03128
Soda, Y., Marumoto, T., Friedmann-Morvinski, D., Soda, M., Liu, F., Michiue, H.,
et al. (2011). Transdifferentiation of glioblastoma cells into vascular endothelial
cells. Proc. Natl. Acad. Sci. U.S.A. 108, 4274–4280. doi: 10.1073/pnas.
1016030108
Son, M. J., Woolard, K., Nam, D. H., Lee, J., and Fine, H. A. (2009). SSEA-1 is an
enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem
Cell 4, 440–452. doi: 10.1016/j.stem.2009.03.003
Stricker, S. H., Feber, A., Engstrom, P. G., Caren, H., Kurian, K. M., Takashima, Y.,
et al. (2013). Widespread resetting of DNA methylation in glioblastoma-
initiating cells suppresses malignant cellular behavior in a lineage-dependent
manner. Genes Dev. 27, 654–669. doi: 10.1101/gad.212662.112
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn,
M. J., Janzer, R. C., et al. (2009). Effects of radiotherapy with concomitant
and adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of the
EORTC-NCIC trial. Lancet Oncol. 10, 459–466. doi: 10.1016/S1470-2045(09)
70025-7
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn,
M. J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N. Engl. J. Med. 352, 987–996. doi: 10.1056/NEJMoa04
3330
Sugimori, M., Hayakawa, Y., Boman, B. M., Fields, J. Z., Awaji, M., Kozano, H., et al.
(2015). Discovery of power-law growth in the self-renewal of heterogeneous
glioma stem cell populations. PLoS ONE 10:e0135760. doi: 10.1371/journal.
pone.0135760
Suvà, M. L., Rheinbay, E., Gillespie, S. M., Patel, A. P., Wakimoto, H., Rabkin,
S. D., et al. (2014). Reconstructing and reprogramming the tumor-propagating
potential of glioblastoma stem-like Cells. Cell 157, 580–594. doi: 10.1016/j.cell.
2014.02.030
Suva, M. L., Riggi, N., Janiszewska, M., Radovanovic, I., Provero, P., Stehle, J. C.,
et al. (2009). EZH2 is essential for glioblastoma cancer stem cell maintenance.
Cancer Res. 69, 9211–9218. doi: 10.1158/0008-5472.CAN-09-1622
Sweeney, M. D., Ayyadurai, S., and Zlokovic, B. V. (2016). Pericytes of the
neurovascular unit: key functions and signaling pathways. Nat. Neurosci. 19,
771–783. doi: 10.1038/nn.4288
Tamura, K., Aoyagi, M., Ando, N., Ogishima, T., Wakimoto, H., Yamamoto, M.,
et al. (2013). Expansion of CD133-positive glioma cells in recurrent de
novo glioblastomas after radiotherapy and chemotherapy. J. Neurosurg. 119,
1145–1155. doi: 10.3171/2013.7.JNS122417
Tchoghandjian, A., Baeza, N., Colin, C., Cayre, M., Metellus, P., Beclin, C.,
et al. (2010). A2B5 cells from human glioblastoma have cancer stem
cell properties. Brain Pathol. 20, 211–221. doi: 10.1111/j.1750-3639.2009.
00269.x
Thirant, C., Galan-Moya, E. M., Dubois, L. G., Pinte, S., Chafey, P., Broussard, C.,
et al. (2012). Differential proteomic analysis of human glioblastoma and neural
stem cells reveals HDGF as a novel angiogenic secreted factor. Stem Cells 30,
845–853. doi: 10.1002/stem.1062
Tyagi, N., Arora, S., Deshmukh, S. K., Singh, S., Marimuthu, S., and Singh, A. P.
(2016). Exploiting Nanotechnology for the development of microRNA-based
cancer therapeutics. J. Biomed. Nanotechnol. 12, 28–42. doi: 10.1166/jbn.2016.
2172
Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson,
M. D., et al. (2010). Integrated genomic analysis identifies clinically
relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA,
IDH1, EGFR, and NF1. Cancer Cell 17, 98–110. doi: 10.1016/j.ccr.2009.
12.020
Wang, C. H., Chiou, S. H., Chou, C. P., Chen, Y. C., Huang, Y. J., and Peng,
C. A. (2011). Photothermolysis of glioblastoma stem-like cells targeted by
carbon nanotubes conjugated with CD133 monoclonal antibody.Nanomedicine
7, 69–79. doi: 10.1016/j.nano.2010.06.010
Wang, J., Sakariassen, P. O., Tsinkalovsky, O., Immervoll, H., Boe, S. O.,
Svendsen, A., et al. (2008a). CD133 negative glioma cells form tumors in nude
rats and give rise to CD133 positive cells. Int. J. Cancer 122, 761–768. doi:
10.1002/ijc.23130
Wang, J., Wang, H., Li, Z., Wu, Q., Lathia, J. D., McLendon, R. E., et al. (2008b).
c-Myc is required for maintenance of glioma cancer stem cells. PLoS ONE
3:e3769. doi: 10.1371/journal.pone.0003769
Wang, R., Chadalavada, K., Wilshire, J., Kowalik, U., Hovinga, K. E., Geber, A., et al.
(2010). Glioblastoma stem-like cells give rise to tumour endothelium. Nature
468, 829–833. doi: 10.1038/nature09624
Wei, X., Chen, X., Ying, M., and Lu, W. (2014). Brain tumor-targeted drug
delivery strategies. Acta Pharm. Sin. B 4, 193–201. doi: 10.1016/j.apsb.2014.
03.001
Weinberg, R. A. (2008). Coevolution in the tumor microenvironment. Nat. Genet.
40, 494–495. doi: 10.1038/ng0508-494
Wong, A. D., Ye, M., Levy, A. F., Rothstein, J. D., Bergles, D. E., and Searson, P. C.
(2013). The blood-brain barrier: an engineering perspective. Front. Neuroeng.
6:7. doi: 10.3389/fneng.2013.00007
Woodworth, G. F., Dunn, G. P., Nance, E. A., Hanes, J., and Brem, H. (2014).
Emerging insights into barriers to effective brain tumor therapeutics. Front.
Oncol. 4:126. doi: 10.3389/fonc.2014.00126
Wu, S. M., Choo, A. B., Yap, M. G., and Chan, K. K. (2010). Role of
sonic hedgehog signaling and the expression of its components in human
embryonic stem cells. Stem Cell Res. 4, 38–49. doi: 10.1016/j.scr.2009.
09.002
Yahyanejad, S., King, H., Iglesias, V. S., Granton, P. V., Barbeau, L. M., van
Hoof, S. J., et al. (2016). NOTCH blockade combined with radiation therapy
and temozolomide prolongs survival of orthotopic glioblastoma. Oncotarget 7,
41251–41264. doi: 10.18632/oncotarget.9275
Yan, X., Ma, L., Yi, D., Yoon, J. G., Diercks, A., Foltz, G., et al. (2011). A CD133-
related gene expression signature identifies an aggressive glioblastoma subtype
with excessive mutations. Proc. Natl. Acad. Sci. U.S.A. 108, 1591–1596. doi:
10.1073/pnas.1018696108
Yang, Y. P., Chien, Y., Chiou, G. Y., Cherng, J. Y., Wang, M. L., Lo, W. L.,
et al. (2012). Inhibition of cancer stem cell-like properties and reduced
chemoradioresistance of glioblastoma using microRNA145 with cationic
polyurethane-short branch PEI. Biomaterials 33, 1462–1476. doi: 10.1016/j.
biomaterials.2011.10.071
Yao, J., Hsu, C. H., Li, Z., Kim, T. S., Hwang, L. P., Lin, Y. C., et al.
(2015). Magnetic resonance nano-theranostics for glioblastoma multiforme.
Curr. Pharm. Des. 21, 5256–5266. doi: 10.2174/138161282166615092310
3307
Yao, X., Ping, Y., Liu, Y., Chen, K., Yoshimura, T., Liu, M., et al. (2013).
Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a key role
in vasculogenic mimicry formation, neovascularization and tumor initiation
by Glioma stem-like cells. PLoS ONE 8:e57188. doi: 10.1371/journal.pone.005
7188
Yuan, X., Curtin, J., Xiong, Y., Liu, G., Waschsmann-Hogiu, S., Farkas, D. L.,
et al. (2004). Isolation of cancer stem cells from adult glioblastoma multiforme.
Oncogene 23, 9392–9400. doi: 10.1038/sj.onc.1208311
Zbinden, M., Duquet, A., Lorente-Trigos, A., Ngwabyt, S. N., Borges, I., and
Ruiz i Altaba, A. (2010). NANOG regulates glioma stem cells and is essential
in vivo acting in a cross-functional network with GLI1 and p53. EMBO J. 29,
2659–2674. doi: 10.1038/emboj.2010.137
Zeppernick, F., Ahmadi, R., Campos, B., Dictus, C., Helmke, B. M., Becker, N.,
et al. (2008). Stem cell marker CD133 affects clinical outcome in glioma
patients. Clin. Cancer Res. 14, 123–129. doi: 10.1158/1078-0432.CCR-07-
0932
Zhang, N., Wei, P., Gong, A., Chiu, W. T., Lee, H. T., Colman, H., et al. (2011).
FoxM1 promotes beta-catenin nuclear localization and controls Wnt target-
gene expression and glioma tumorigenesis. Cancer Cell 20, 427–442. doi: 10.
1016/j.ccr.2011.08.016
Zheng, H., Ying, H., Wiedemeyer, R., Yan, H., Quayle, S. N., Ivanova, E. V.,
et al. (2010). PLAGL2 regulates Wnt signaling to impede differentiation in
neural stem cells and gliomas. Cancer Cell 17, 497–509. doi: 10.1016/j.ccr.2010.
03.020
Frontiers in Pharmacology | www.frontiersin.org 13 December 2016 | Volume 7 | Article 477
fphar-07-00477 December 7, 2016 Time: 12:19 # 14
Yi et al. Understanding and Targeting the GSCs
Zhong, X., Liu, X., Li, Y., Cheng, M., Wang, W., Tian, K., et al. (2016). HMGA2
sustains self-renewal and invasiveness of glioma-initiating cells. Oncotarget 7,
44365–44380. doi: 10.18632/oncotarget.9744
Zhou, Q., Guo, P., and Gallo, J. M. (2008). Impact of angiogenesis inhibition
by sunitinib on tumor distribution of temozolomide. Clin. Cancer Res. 14,
1540–1549. doi: 10.1158/1078-0432.CCR-07-4544
Zhu, X. Y., Wang, L., Luan, S. H., Zhang, H. S., Huang, W. T., and Wang, N. H.
(2014). The PGI-KLF4 pathway regulates self-renewal of glioma stem cells
residing in the mesenchymal niches in human gliomas. Neoplasma 61, 401–410.
doi: 10.4149/neo_2014_049
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Yi, Hsieh, Huang, Li and Zhao. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 14 December 2016 | Volume 7 | Article 477
